Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL
NCT04160442 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46
Last updated 2020-12-11
Summary
The goal of this project is to test the feasibility of a Patient Preferences in Shared Decision-Making encounter tool (PPSDM) in the clinical context of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). This project will evaluate the feasibility of a shared decision-making (SDM) model that employs an "encounter tool"1 to facilitate SDM at the point of a treatment decision for patients with DLBCL and FL.
Conditions
Interventions
- BEHAVIORAL
-
Carevive CarePlanning System
Subject will complete brief survey prior to seeing provider in clinic. Utilizing the CarePlanning System, the provider will review the subject's responses directing the conversation and treatment decision will be made. A treatment careplan will be developed and given to the subject.
Sponsors & Collaborators
-
Carevive Systems, Inc.
lead INDUSTRY
Principal Investigators
-
Debbie Wujcik, PhD,RN · Carevive Systems, Inc.
Study Design
- Allocation
- NA
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-01-16
- Primary Completion
- 2020-06-30
- Completion
- 2020-06-30
Countries
- United States
Study Locations
More Related Trials
-
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
NCT05255354 ·Status: RECRUITING
-
Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02708732 ·Status: COMPLETED
-
Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life
NCT06026644 ·Status: ACTIVE_NOT_RECRUITING
-
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
NCT00058227 ·Status: COMPLETED ·Phase: PHASE1
-
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00274924 ·Status: COMPLETED ·Phase: PHASE2
-
R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL
NCT03018626 ·Status: UNKNOWN ·Phase: PHASE3
-
Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma
NCT03797170 ·Status: UNKNOWN
-
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
NCT01340443 ·Status: COMPLETED
-
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02596971 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region
NCT04859920 ·Status: COMPLETED
-
Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma
NCT02474550 ·Status: UNKNOWN
-
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
NCT03837873 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
NCT03685344 ·Status: TERMINATED ·Phase: PHASE1
-
Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
NCT00556127 ·Status: COMPLETED ·Phase: PHASE2
-
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
NCT06779435 ·Status: RECRUITING
-
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
NCT02529852 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
NCT00324831 ·Status: SUSPENDED ·Phase: PHASE3
-
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07197307 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
NCT04113226 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors
NCT03283202 ·Status: COMPLETED ·Phase: PHASE1
-
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT06683885 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes
NCT04319237 ·Status: COMPLETED
-
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
NCT03104478 ·Status: COMPLETED
-
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
NCT02257567 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
NCT05800405 ·Status: RECRUITING ·Phase: EARLY_PHASE1